Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
23 hedge funds and large institutions have $16.7M invested in Bellerophon Therapeutics, Inc. in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
12% less funds holding
Funds holding: 26 → 23 (-3)
37% less capital invested
Capital invested by funds: $26.5M → $16.7M (-$9.73M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$74.9K |
| 2 |
VF
Virtu Financial
New York
|
+$14.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12.5K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$4.6K |
| 5 |
LPL Financial
San Diego,
California
|
+$4.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.2M |
| 2 |
TI
Telemetry Investments
New York
|
-$92.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23.9K |
| 4 |
BlackRock
New York
|
-$11K |
| 5 |
Goldman Sachs
New York
|
-$8K |
BLPH Hedge Fund Activity: Q3 2019 in Review
23 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q3 2019, worth a combined $16.7M — down 37% from $26.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BLPH and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $74.9K. The largest seller was Armistice Capital, cutting an estimated $1.2M.
- 23 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q3 2019, down from 26 in Q2 2019.
- Funds reported $16.7M of Bellerophon Therapeutics, Inc. stock for Q3 2019, down 37% quarter-over-quarter.
- 2 funds opened new Bellerophon Therapeutics, Inc. positions in Q3 2019 and 5 closed out, a net change of -3 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q3 2019 was Renaissance Technologies, an estimated $74.9K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q3 2019 was Armistice Capital, an estimated $1.2M sold.
Based on aggregated 13F filings for Q3 2019.